

March 27, 2024



# IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

## ***Overview of U.S. Commercial Strategy will be Discussed on Conference Call***

CAESAREA, Israel, March 27, 2024 /PRNewswire/ -- [IceCure Medical Ltd.](#) (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended December 31, 2023 before the Nasdaq Stock Market opens on Wednesday, April 3, 2024.



Eyal Shamir, Chief Executive Officer, and Ronen Tsimmerman, Chief Financial Officer, will discuss the operating and financial results, and other corporate developments on a conference call at 10:00 a.m. EDT on the same day. Additionally, Shad Good, Vice President of Sales for North America, will provide an overview of the Company's commercial strategy to drive market adoption of the ProSense® System.

## **Conference call & webcast info:**

Wednesday, April 3, 2024, at 10:00 am EDT

US: 1-888-407-2553

Israel/International: +972-3-9180696

A live webcast will be available at: [veidan.activetrail.biz/IcecureQ4-2023](https://veidan.activetrail.biz/IcecureQ4-2023)

A recording of the webcast will be available at: [ir.icecure-medical.com/](https://ir.icecure-medical.com/)

## **About ProSense®**

The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid

nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver.

ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedure for breast tumors.

## **About IceCure Medical**

IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

## **Forward Looking Statements**


This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses that it will report its financial and operational results as of and for the twelve months ended December 31, 2023 on April 3, 2024 and also discuss such results, other corporate developments, and the Company's commercial strategy in driving market adoption of the ProSense® system on a conference call on the same day. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on the SEC's website, [www.sec.gov](http://www.sec.gov). The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

## **IR Contact:**

Email: [investors@icecure-medical.com](mailto:investors@icecure-medical.com)

Michael Polyviou  
Phone: 732-232-6914  
Todd Kehrli  
Phone: 310-625-4462

Logo - [https://mma.prnewswire.com/media/2319310/IceCure\\_Medical\\_Logo.jpg](https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg)

 View original content: <https://www.prnewswire.com/news-releases/icecure-medical-to-report-2023-full-year-financial--operational-results-on-april-3-2024-302100961.html>

SOURCE IceCure Medical